Comparative Pharmacology
Head-to-head clinical analysis: HY PAM 25 versus HYDRO SERP 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HY PAM 25 versus HYDRO SERP 50.
HY-PAM "25" vs HYDRO-SERP "50"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
Hydrochlorothiazide 50 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination